Related references
Note: Only part of the references are listed.Radiosynthesis of [N-13]dantrolene, a positron emission tomography probe for breast cancer resistant protein, using no-carrier-added [N-13]ammonia
Katsushi Kumata et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan
Z. Garami et al.
EJSO (2012)
Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer
Sietske B. M. Gaykema et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21-18F-Fluoro-16α,17α-[(R)-(1′-α-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione
Farrokh Dehdashti et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma
Michel van Kruchten et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Validity of Simplified 3′-Deoxy-3′-[18F]Fluorothymidine Uptake Measures for Monitoring Response to Chemotherapy in Locally Advanced Breast Cancer
Mark Lubberink et al.
MOLECULAR IMAGING AND BIOLOGY (2012)
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Sarah J. Conley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Interpretation of Positron Emission Mammography and MRI by Experienced Breast Imaging Radiologists: Performance and Observer Reproducibility
Deepa Narayanan et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2011)
Synthesis and in vivo evaluation of 18F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters
Kazunori Kawamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein
Bernd Doerner et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
[18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel
Kaiyumars B. Contractor et al.
CLINICAL CANCER RESEARCH (2011)
PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake
Lisa K. Dunnwald et al.
CLINICAL CANCER RESEARCH (2011)
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
David Groheux et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET
Gabriela Kramer-Marek et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Quantification of receptor-ligand binding with [18F]fluciclatide in metastatic breast cancer patients
Giampaolo Tomasi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Human Dosimetry and Preliminary Tumor Distribution of 18F-Fluoropaclitaxel in Healthy Volunteers and Newly Diagnosed Breast Cancer Patients Using PET/CT
Karen A. Kurdziel et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening
Nicolas Tournier et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PET
Brenda F. Kurland et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer
Lanell M. Peterson et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice
Kristin McLarty et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer
Melinda Wuest et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography
Kaiyumars B. Contractor et al.
NUCLEAR MEDICINE COMMUNICATIONS (2011)
The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities
Vasiliki Filippi et al.
NUCLEAR MEDICINE COMMUNICATIONS (2011)
Novel PET biomarkers for breast cancer imaging
Laura M. Kenny et al.
NUCLEAR MEDICINE COMMUNICATIONS (2011)
Ga-68-NODAGA-RGDyK for alpha(v)beta(3) integrin PET imaging Preclinical investigation and dosimetry
F. Buchegger et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2011)
Pilot Pharmacokinetic and Dosimetric Studies of 18F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging αvβ3 Integrin Levels
Erik S. Mittra et al.
RADIOLOGY (2011)
PET Imaging of Integrin alpha V beta 3 Expression
Ambros J. Beer et al.
THERANOSTICS (2011)
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor
Florian Bauer et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy
Guus A. M. S. van Dongen et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Detection of Synchronous Primary Breast and Prostate Cancer by F-18 Fluorocholine PET/CT
Sandi A. Kwee et al.
CLINICAL NUCLEAR MEDICINE (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Radionuclide imaging of perfusion and hypoxia
George Laking et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Biopharmaceutical benchmarks 2010
Gary Walsh
NATURE BIOTECHNOLOGY (2010)
Receptor conversion in distant breast cancer metastases
Laurien D. C. Hoefnagel et al.
BREAST CANCER RESEARCH (2010)
[11C]Choline Positron Emission Tomography in Estrogen Receptor-Positive Breast Cancer
Kaiyumars B. Contractor et al.
CLINICAL CANCER RESEARCH (2009)
Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET
Ambros J. Beer et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration
Maria Mikhaylova et al.
NEOPLASIA (2008)
18F-fluoroestradiol
Lavanya Sundararajan et al.
SEMINARS IN NUCLEAR MEDICINE (2007)
Imaging early changes in proliferation at 1 week post chemotherapy:: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography
Laura Kenny et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
S. A. Hussain et al.
BRITISH JOURNAL OF CANCER (2007)
Positron emission tomography in patients with breast cancer using 18F-3′-deoxy-3′-fluoro-L-thymidine (18F-FLT) -: a pilot study
LB Been et al.
EJSO (2006)
Hypoxia and glucose metabolism in malignant tumors:: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging
JG Rajendran et al.
CLINICAL CANCER RESEARCH (2004)
18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement of breast cancer
G Zornoza et al.
EJSO (2004)
F-18-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer
G Zornoza et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2004)
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression
A Ramírez de Molina et al.
CANCER RESEARCH (2004)